Pricing -The New Compliance Frontier
By: Seth Whitelaw, JD, LLM, SJD, Editor and Kaitlin Fallon, Esq., Staff Writer for Life Science Compliance Update
The U.S. Senate Finance Committee recently released a report on the pricing of Gilead’s hepatitis C drug, Sovaldi. After reviewing over 20,000 internal company documents, Senators Wyden (D-OR) and Grassley (D-IA) concluded that Gilead pursued a revenue driven strategy. This article explores the report and its implications for life science compliance programs.